Status:
COMPLETED
Pronostic Value of Type I ANTi-Interferon Antibodies in Patients With COVID-19 Acute Respiratory Failure
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Acute Respiratory Failure
Eligibility:
All Genders
18+ years
Brief Summary
Severe SARS-CoV-2 infections are frequently associated with the acute respiratory distress syndrome (ARDS), which leads to a mortality of 30-40%. An altered type I interferon (IFN) response has been d...
Detailed Description
Severe SARS-CoV-2 infections are frequently associated with the acute respiratory distress syndrome (ARDS), which leads to a mortality of 30-40%. An altered type I interferon (IFN) response has been d...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- SARS-CoV-2 infection with a positive PCR
- Patient admitted in the ICU for acute respiratory failure (SpO2≤90% and need for supplemental oxygen or any kind of ventilator support)
- Patient or next of keen was informed of study inclusion
Exclusion
- • Patient with SARS-CoV-infection but no acute respiratory failure
Key Trial Info
Start Date :
November 20 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 30 2021
Estimated Enrollment :
1022 Patients enrolled
Trial Details
Trial ID
NCT04733105
Start Date
November 20 2020
End Date
October 30 2021
Last Update
November 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assistance Publique Hôpitaux de Paris - CHU HENRI MONDOR
Créteil, France, 94010